Christian Leisner has led several global programs with new biologic entities including LME636 (Novartis) from the preclinical stage up through successful Phase 2. He has also played lead roles in the clinical development of Rydapt® (approved in rare hematological disease) and Beovu® (approved in wetAMD).

Christian has also served in Business Development & Licensing teams in Alcon and Novartis and was part of the senior management in ESBATech. He obtained his Ph.D. in biochemistry from ETH Zurich, Switzerland. In addition, he holds a Master of Science in Molecular Biology and in Chemistry from Roskilde University, Denmark.